US52635N1037
US52635N1037
LENZ Therapeutics, Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 114.53M EUR | 178.45M EUR | 286.89M EUR | 501.52M EUR |
Enterprise Value | -108.52M EUR | 154.81M EUR | 262.79M EUR | 477.15M EUR |
Valuation Multiples | ||||
Trailing P/E | -- | -- | -- | -- |
Forward P/E | -1.19x | -- | -- | -- |
Price to Sales | 5.33x | 8.31x | 13.67x | 26.27x |
Price to Book | 0.52x | 0.81x | 1.16x | 1.76x |
EV/Revenue | -5.05x | 7.21x | 12.52x | 25x |
EV/EBITDA | 0.8x | -- | -- | -- |
Price to FCF (P/FCF) | -- | -- | -- | -- |
EV/FCF | -- | -- | -- | -- |
FCF Yield | -62.21% | -64.12% | -30.48% | -10.74% |